MedPath
HSA Approval

ESCOPRO POWDER FOR SOLUTION FOR INJECTION/INFUSION 40MG/VIAL

SIN17003P

ESCOPRO POWDER FOR SOLUTION FOR INJECTION/INFUSION 40MG/VIAL

ESCOPRO POWDER FOR SOLUTION FOR INJECTION/INFUSION 40MG/VIAL

May 8, 2024

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS

Medical Information

A02BC05

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

IMMACULE LIFESCIENCES PRIVATE LIMITED

Active Ingredients

ESOMEPRAZOLE SODIUM EQUIVALENT TO ESOMEPRAZOLE

40mg/vial

Esomeprazole

Documents

Package Inserts

Escopro Powder for Solution for Injection Infusion_PI.pdf

Approved: May 8, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ESCOPRO POWDER FOR SOLUTION FOR INJECTION/INFUSION 40MG/VIAL - HSA Approval | MedPath